Your browser doesn't support javascript.
Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease.
Hovanesian, John A; Nichols, Kelly K; Jackson, Mitchell; Katz, James; Chan, Arthur; Glassberg, Mrudula B; Sloesen, Brigitte; Korves, Caroline; Nguyen, Catherine; Syntosi, Annie.
  • Hovanesian JA; Harvard Eye Associates, Laguna Hills, CA, USA.
  • Nichols KK; UCLA Jules Stein Eye Institute, Los Angeles, CA, USA.
  • Jackson M; School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Katz J; Jacksoneye, Lake Villa, IL, USA.
  • Chan A; The Midwest Center for Sight, Des Plaines, IL, USA.
  • Glassberg MB; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Sloesen B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Korves C; Novartis Pharma AG, Basel, Switzerland.
  • Nguyen C; Analysis Group, Inc., Boston, MA, USA.
  • Syntosi A; Analysis Group, Inc., Los Angeles, CA, USA.
Clin Ophthalmol ; 15: 1041-1054, 2021.
Article in English | MEDLINE | ID: covidwho-1140597
Semantic information from SemMedBD (by NLM)
1. Dry Eye Syndromes PROCESS_OF Patients
Subject
Dry Eye Syndromes
Predicate
PROCESS_OF
Object
Patients
2. lifitegrast TREATS Dry Eye Syndromes
Subject
lifitegrast
Predicate
TREATS
Object
Dry Eye Syndromes
3. AATF gene|AATF PART_OF Patients
Subject
AATF gene|AATF
Predicate
PART_OF
Object
Patients
4. AATF gene|AATF PART_OF Ophthalmologist (occupation)
Subject
AATF gene|AATF
Predicate
PART_OF
Object
Ophthalmologist (occupation)
5. Treatment Ongoing PROCESS_OF Patients
Subject
Treatment Ongoing
Predicate
PROCESS_OF
Object
Patients
6. Therapeutic procedure USES lifitegrast
Subject
Therapeutic procedure
Predicate
USES
Object
lifitegrast
7. Dry Eye Syndromes PROCESS_OF Patients
Subject
Dry Eye Syndromes
Predicate
PROCESS_OF
Object
Patients
8. lifitegrast TREATS Dry Eye Syndromes
Subject
lifitegrast
Predicate
TREATS
Object
Dry Eye Syndromes
9. AATF gene|AATF PART_OF Patients
Subject
AATF gene|AATF
Predicate
PART_OF
Object
Patients
10. AATF gene|AATF PART_OF Ophthalmologist (occupation)
Subject
AATF gene|AATF
Predicate
PART_OF
Object
Ophthalmologist (occupation)
11. Treatment Ongoing PROCESS_OF Patients
Subject
Treatment Ongoing
Predicate
PROCESS_OF
Object
Patients
12. Therapeutic procedure USES lifitegrast
Subject
Therapeutic procedure
Predicate
USES
Object
lifitegrast
ABSTRACT

Purpose:

This study evaluated real-world treatment of dry eye disease (DED) with lifitegrast. Patients and

Methods:

Ophthalmologists and optometrists treating patients with DED were invited to participate through a healthcare provider (HCP)-based panel. HCPs completed a provider survey and contributed data toward a chart review for up to five qualifying patients with DED who initiated lifitegrast ophthalmic solution (index date) between 01/01/2017 (US) or 01/01/2018 (Canada) and 06/30/2019. Patient demographics, treatments, clinical characteristics, and outcomes (ie, severity, signs, symptoms) were collected for the 6-month pre-index period and up to 12-months post-index.

Results:

For this study, 517 HCPs contributed 600 patient charts. Among 554 and 281 patients with follow-up at 6 and 12-months post-index, 512 (92.4%) and 238 (84.7%) patients had ongoing lifitegrast treatment, respectively. Other DED-related treatments were less frequently used post-index with lifitegrast vs pre-index over-the-counter artificial tear use (45.2% vs 75.5%), topical corticosteroids (3.8% vs 18.8%), any cyclosporine (3.0% vs 20.5%). At 3-months (n=571) and 12-months (n=320) post-index vs pre-index, fewer patients had eye dryness (47 [8.2%] and 16 [5.0%] vs 525 [87.5%]), blurred vision (28 [4.9%] and 11 [3.4%] vs 346 [57.7%]), ocular burning/stinging (25 [4.4%] and 8 [2.5%] vs 336 [56.0%]), depression (8 [1.4%] and 9 [2.8%] vs 55 [9.2%]), fatigue (4 [0.7%] and 1 [0.3%] vs 82 [13.7%]), and headache (1 [0.2%] and 0 vs 19 [3.2%]). At 3 and 12-months post-index vs pre-index, average corneal staining score was numerically lower (2.7 and 2.0 vs 6.5), and average Schirmer score (10.6 and 10 vs 6.3) and tear film break-up time (7.3 and 8.0 vs 4.8) higher.

Conclusion:

The majority of patients had ongoing lifitegrast treatment 6-months post-index with reduction in overall treatment burden. Improvement in DED signs and symptoms, including QoL impacts, was evident at 3 months and up to 12 months after lifitegrast initiation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Observational study Language: English Journal: Clin Ophthalmol Clinical aspect: Prognosis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Observational study Language: English Journal: Clin Ophthalmol Clinical aspect: Prognosis Year: 2021
...